^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD19 positive

    i
    Other names: CD19, CD19 Molecule, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, Differentiation Antigen CD19, B-Lymphocyte Antigen CD19, CD19 Antigen, CVID3, B4
    Entrez ID:
    930
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1m
    Immunophenotypic properties association of CLL and ALL patient cells by flow cytometry analysis. (PubMed, J Taibah Univ Med Sci)
    In patients with CLL, there was a strong positive correlation between the number of CD19-positive cells and the number of cells expressing CD5, CD20, CD23, and CD200. Additionally, in patients with ALL, there was a positive correlation of CD79 and CD99 with the number of CD19-positive cells.
    Journal
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • CD200 (CD200 Molecule) • CD99 (CD99 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD19 positive • CD20 expression • CD34 positive
    1m
    CYTB323A12101: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (clinicaltrials.gov)
    P1/2, N=225, Recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> May 2028
    Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Imbruvica (ibrutinib) • rapcabtagene autoleucel (YTB323)
    2ms
    Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P2, N=60, Recruiting, Juventas Cell Therapy Ltd. | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • Yuanruida (inaticabtagene autoleucel)
    6ms
    GMALL-BLIVEN: Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) (clinicaltrials.gov)
    P1/2, N=39, Recruiting, Goethe University | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    Venclexta (venetoclax) • Blincyto (blinatumomab)
    6ms
    EWALL-BOLD: Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab (clinicaltrials.gov)
    P2, N=52, Completed, Goethe University | Recruiting --> Completed | Trial primary completion date: Sep 2023 --> Jan 2024
    Trial completion • Trial primary completion date
    |
    CD19 positive
    |
    Blincyto (blinatumomab)
    6ms
    MINDway: Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, MorphoSys AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 positive
    |
    lenalidomide • Monjuvi (tafasitamab-cxix)
    6ms
    Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=36, Recruiting, Mehrdad Abedi, MD | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Aug 2024 --> May 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 positive
    |
    Rituxan (rituximab) • cyclophosphamide • Truxima (rituximab-abbs) • fludarabine IV
    6ms
    D7400C00006: A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=206, Recruiting, AstraZeneca | N=116 --> 206
    Enrollment change
    |
    CD19 positive
    |
    AZD0486
    6ms
    Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy. (PubMed, Haematologica)
    Loncastuximab tesirine was more potent than other anti-CD19 ADCs (coltuximab ravtansine, huB4-DGN462), albeit the pattern of activity across cell lines was correlated. Loncastuximab tesirine activity was also largely correlated with cell line sensitivity to R-CHOP...Our data support the further development of loncastuximab tesirine as a single agent and in combination for patients affected by mature B-cell neoplasms. The results also highlight the importance of CD19 expression and the existence of lymphoma populations characterized by resistance to multiple therapies.
    Preclinical • Journal • Combination therapy • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    Rituxan (rituximab) • Zynlonta (loncastuximab tesirine-lpyl) • coltuximab ravtansine (SAR3419)
    7ms
    Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, University of Colorado, Denver | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    UCD19 CAR T Cells
    7ms
    TRANSCEND-CLL-004: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (clinicaltrials.gov)
    P1/2, N=209, Recruiting, Juno Therapeutics, a Subsidiary of Celgene | Active, not recruiting --> Recruiting | Trial completion date: Jul 2026 --> Nov 2027 | Trial primary completion date: Jul 2026 --> Nov 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    PLCG2 (Phospholipase C Gamma 2) • CD5 (CD5 Molecule)
    |
    CD19 positive • PLCG2 mutation
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Breyanzi (lisocabtagene maraleucel)
    7ms
    Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2024 --> Oct 2024 | Trial primary completion date: Apr 2024 --> Oct 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    CD19 positive
    |
    Keytruda (pembrolizumab) • Blincyto (blinatumomab)
    7ms
    Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration) (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
    New P2 trial
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • ssCART-19
    7ms
    huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=55, Terminated, Fred Hutchinson Cancer Center | Active, not recruiting --> Terminated; Terminated due to slow enrollment and end of funding
    Trial termination • CAR T-Cell Therapy
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • SELL (Selectin L)
    |
    CD19 positive • CD8 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative • CD4 expression
    |
    cyclophosphamide • fludarabine IV • JCAR014
    7ms
    EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia. (PubMed, Cell Commun Signal)
    Doxorubicin displayed a selective killing of EP300-ZNF384-positive B-ALL cells in vitro and in vivo. Collectively, we identify IL3RA as a direct downstream target of EP300-ZNF384, suggesting CD123 is a potent biomarker for EP300-ZNF384-driven B-ALL. Targeting CD123 may be a novel therapeutic approach to EP300-ZNF384-positive patients, alternative or, more likely, complementary to standard chemotherapy regimen in clinical setting.
    Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • EP300 (E1A binding protein p300) • IL3RA (Interleukin 3 Receptor Subunit Alpha) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • ZNF384 (Zinc Finger Protein 384)
    |
    CD19 positive • CD123 expression • IL3RA expression
    |
    doxorubicin hydrochloride
    7ms
    A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation. (PubMed, J Exp Clin Cancer Res)
    This study demonstrates a novel high-content and high-throughput screen can identify drugs to enhance CAR T cell activity. This and other high-content technologies will pave the way to develop clinical trials implementing rational drug plus CAR T cell combinatorial therapies. Importantly, the technique could also be repurposed for an array of basic and translational research applications where drugs are needed to modulate cell surface protein expression.
    FDA event • Journal • CAR T-Cell Therapy
    |
    CD276 (CD276 Molecule) • PRKCA (Protein Kinase C Alpha)
    |
    CD19 positive • CD276 expression
    |
    B7-H3 CAR-T
    8ms
    CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment. (PubMed, Biomed Pharmacother)
    Compared to GBM spheroids, the presence of pericytes significantly enhanced CD19 CAR-iNK cell migration towards GBM and reduced proliferation. These results underline the efficacy of CD19 CAR-iNK cells in targeting pericytes within the GBM TME, suggesting their potential therapeutic value for GBM treatment.
    Journal
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    8ms
    Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, University of Maryland, Baltimore | Trial completion date: Nov 2024 --> Aug 2027
    Trial completion date • Minimal residual disease
    |
    CD81 (CD81 Molecule)
    |
    CD19 positive
    |
    Blincyto (blinatumomab)
    8ms
    Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL (clinicaltrials.gov)
    P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    8ms
    CAR19T2: CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Zhujiang Hospital | N=70 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • CAR T-Cell Therapy
    |
    CD19 positive
    |
    cyclophosphamide • CAR19T2 T cells
    8ms
    Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • fludarabine IV
    8ms
    Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=80, Not yet recruiting, Juventas Cell Therapy Ltd. | Initiation date: Oct 2023 --> Aug 2024
    Trial initiation date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • CD22 (CD22 Molecule)
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • HY004
    8ms
    Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P2, N=60, Recruiting, Juventas Cell Therapy Ltd. | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • Yuanruida (inaticabtagene autoleucel)
    8ms
    GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (clinicaltrials.gov)
    P1/2, N=36, Recruiting, AO GENERIUM | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    GNR-084
    9ms
    CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, Crystal Mackall, MD | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 positive • CD19 expression • CD22 expression
    |
    cyclophosphamide • fludarabine IV • NKTR-255
    9ms
    Direct and Indirect Chimeric Antigen Receptor T-Cell Imaging with PET/MRI in a Tumor Xenograft Model. (PubMed, Radiology)
    © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Bulte in this issue
    Preclinical • Journal • CAR T-Cell Therapy
    |
    SSTR (Somatostatin Receptor)
    |
    CD19 positive
    9ms
    Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia (clinicaltrials.gov)
    P1, N=60, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Jan 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • CD19-CAR.CD45RA- negative T-cells
    9ms
    Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    lenalidomide • Blincyto (blinatumomab)
    9ms
    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
    10ms
    Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma. (PubMed, Front Pediatr)
    However, salvage therapies for relapsed large B-cell lymphoma after CART19 cell therapy have not been fully explored and are conducted based on clinicians' case-by-case decisions. In this review, we will focus on salvage therapies reported to date and discuss the management of relapsed/refractory large B-cell lymphomas after CART19 cell therapy.
    Review • Journal • CAR T-Cell Therapy • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
    |
    CD19 positive • CD19 expression
    11ms
    UHKT-CAR19-01: CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma (clinicaltrials.gov)
    P1, N=10, Recruiting, Institute of Hematology and Blood Transfusion, Czech Republic | Trial completion date: Jun 2028 --> Jun 2025 | Trial primary completion date: Jun 2027 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    11ms
    TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II (clinicaltrials.gov)
    P1/2, N=90, Recruiting, Tanja Andrea Gruber | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    CD19 positive
    |
    bortezomib • Blincyto (blinatumomab) • Zolinza (vorinostat) • dexamethasone • mitoxantrone • ziftomenib (KO-539) • mercaptopurine
    11ms
    Scalable generation of functional human iPSC-derived CAR-macrophages that efficiently eradicate CD19-positive leukemia. (PubMed, J Immunother Cancer)
    In summary, our work provides insights into the seminal use and behavior of CAR-macrophages which are derived from various sources of stem cells, while introducing a unique technology for CAR-macrophage manufacturing, all dedicated to the clinical translation of CAR-macrophages within the field of anticancer immunotherapies.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    11ms
    Reprogramming of human γδ T cells by expression of an anti-CD19 TCR fusion construct (εTRuC) to enhance tumor killing. (PubMed, J Leukoc Biol)
    Here, we express an anti-CD19 εTRuC in primary γδ T cells that were expanded using zoledronate (Zol) or concanavalin A. We show that the resulting εTRuC γδ T cells were reprogrammed to better recognize CD19-positive B cell tumors and-in case of the Zol-expanded cells-a CD19-expressing colon adenocarcinoma-derived cell line in vitro...Finally, addition of vitamin C promoted the recovery of larger γδ T cell numbers after lentiviral transduction, as used for the expression of the εTRuC. In conclusion, the generation and use of γδ εTRuC T cells might be a new approach for cancer immunotherapy.
    Journal • IO biomarker
    |
    CD19 (CD19 Molecule) • IL2RA (Interleukin 2 receptor, alpha) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    |
    CD19 positive • CD19 expression
    |
    zoledronic acid
    11ms
    Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia. (PubMed, Blood Cell Ther)
    Tocilizumab and steroids are the major interventions for controlling cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS)...The combination of ruxolitinib and steroids effectively controlled severe CRS without impeding CAR-T cell expansion...Switching targets and eliminating residual CD7+ CAR-T cells in the blood are key points for patients who relapse after CD7+ CAR-T cell therapy. CAR-T cell therapies for AML have not been investigated in a large-scale cohort, except for CD19-positive AML with the AML1-ETO fusion gene.
    Journal • CAR T-Cell Therapy
    |
    CD7 (CD7 Molecule)
    |
    CD19 positive
    |
    Jakafi (ruxolitinib) • Actemra IV (tocilizumab)
    11ms
    a Phase I Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Chongqing Precision Biotech Co., Ltd
    New P1 trial • CAR T-Cell Therapy
    |
    CD19 positive
    |
    pCAR-19B
    11ms
    D7400C00006: A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=116, Recruiting, AstraZeneca | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    AZD0486
    11ms
    Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, University of Maryland, Baltimore | Trial completion date: Nov 2025 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Jun 2024
    Trial completion date • Trial primary completion date • Minimal residual disease
    |
    CD81 (CD81 Molecule)
    |
    CD19 positive
    |
    Blincyto (blinatumomab)
    11ms
    Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=36, Recruiting, C. Babis Andreadis | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    11ms
    A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) (clinicaltrials.gov)
    P2, N=104, Completed, Juno Therapeutics, a Subsidiary of Celgene | Active, not recruiting --> Completed | N=41 --> 104
    Trial completion • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD19 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Breyanzi (lisocabtagene maraleucel)
    12ms
    Efficacy of FKC889 in relapsed/refractory acute lymphoblastic leukemia: A Phase II single-arm, multicenter, open trial to evaluate the efficacy and safety of FKC889 in adult patients with relapsed/refractory precursor B-cell acute lymphoblastic leukemia (r/r ALL) (ChiCTR2300073872)
    P2, N=28, Not yet recruiting, Peking University People's Hospital; Fosun Kite Biotechnology Co., Ltd
    New P2 trial
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive • CD19 expression
    |
    Tecartus (brexucabtagene autoleucel)
    12ms
    Phase I clinical study on the safety and effectiveness of ECAR-T (Enhanced receptor and chimeric antigen receptor - modified PD1-positive T cell) in the treatment of CD19-positive relapsed or refractory non-Hodgkin's lymphoma (ChiCTR2200058936)
    P1, N=29, Recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-1 (Programmed cell death 1)
    |
    CD19 positive • CD20 negative • PD-1 positive
    |
    Loqtorzi (toripalimab-tpzi)